Zentalis Pharmaceuticals $80.5M Public Offering

Zentalis Pharmaceuticals, a clinical oncology company, announced the pricing of an underwritten public offering of 23 million shares of common stock at $3.50 per share, expecting gross proceeds of approximately $80.5 million. The offering is expected to close on August 17, 2026. The company granted underwriters a 30-day option to purchase up to an additional 3.45 million shares. Proceeds will fund clinical trials, preclinical studies, regulatory filings, manufacturing, and general corporate purposes. The offering is led by joint bookrunners Toronto-Dominion Bank — TD Cowen, Guggenheim Partners, and Oppenheimer & Co., with H.C. Wainwright as passive bookrunner and Rodman & Renshaw as manager. The offering is made under an effective shelf registration statement filed with the SEC.